"A billion-dollar diabetes company that's previously refused to write Ozempic prescriptions is now changing its tune - right as the drugs are about to get a lot cheaper. Omada Health, the chronic care startup that went public in June, said Thursday it would start prescribing GLP-1 medications for obesity. Until now, Omada has stayed out of the GLP-1 prescribing game, leaving those decisions up to patients' primary care providers."
"A few hours earlier, President Donald Trump announced a deal to significantly lower the out-of-pocket cost of GLP-1 drugs, in the range of $50 to $350 a month. Currently, a monthly dose can cost over $1,000. CEO Sean Duffy said during Omada's third-quarter earnings call on Thursday that the company will start offering GLP-1 prescriptions in the first half of 2026."
Omada Health will start prescribing GLP-1 medications for obesity in the first half of 2026. Omada previously refrained from prescribing GLP-1s, leaving prescription decisions to patients' primary care providers. A separate deal will significantly lower out-of-pocket GLP-1 costs to about $50–$350 per month, down from monthly doses that can exceed $1,000. Earlier statements indicated weak direct member demand for prescribing through Omada. Feedback from primary care providers and employer customers cited the rapidly changing GLP-1 landscape, varied medication types, and differing price points as reasons to have Omada take on prescribing responsibilities.
Read at Business Insider
Unable to calculate read time
Collection
[
|
...
]